Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma

Clinical Oncology

Volumn 15, Issue 3, 2003, Pages 132-135

  Tas, Faruk ^a   Camlica, H ^a   Kurul, S ^a   Aydiner, A ^a   Topuz, E ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Docetaxel; Irinotecan; Malignant melanoma; Metastatic

Indexed keywords

DOCETAXEL; INTERFERON; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; FEMALE; FEVER; HUMAN; LEUKOPENIA; MALE; MELANOMA; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; STATISTICAL ANALYSIS; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037731586     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2003.0205     Document Type: Article

References (11)

1. Khayat D, Coeffic D, Antoine E-C. Overview of medical treatments of metastatic malignant melanoma. ASCO Educational Book Spring, 2000;414-427.
2. Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994;30A: 1061-1064.
3. Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 1995;13: 2895-2899.
4. Chou T-C, Motzer R, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth. A rational approach to clinical protocol design. J Natl Cancer Inst 1994;86: 1517-1524.
5. Okishio K, Kudoh S, Hirata K. Schedule dependent additive effect of docetaxel and irinotecan in vitro. Proc Jpn J Cancer Res 1995;86: 619.
6. Bissery MC, Couteau C, Oulid-Aissa D, Armand JP. Docetaxel in combination with irinotecan: Prediction of clinical maximum tolerated dose. Proc Am Soc Clin Oncol 1997;16: 221a.
7. Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996;88: 734-741.
8. Adjei AA, Klein CE, Kastrissios H, et al. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol 2000;18: 1116-1123.
9. Masuda N, Negoro S, Kudoh S, et al. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. J Clin Oncol 2000;18: 2996-3003.
10. Couteau C, Risse M-L, Ducreux M, et al. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J Clin Oncol 2000;18: 3545-3552.
11. Takeda K, Negoro S, Masuda N, et al. Phase I study of Docetaxel (Doc) and Irinotecan (CPT-11) for previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999;18: 524a.